Multicenter Retrospective Study on Streptobacillus Moniliformis Infections in France
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Retrospective study of the effectiveness of antibiotic therapy initiated for the treatment of Streptobacillus moniliformis infection.
Study Overview
Brief Summary
French data on Streptobacillus moniliformis infections (zoonosis transmitted by rat bites) are rare and there are no case series in the literature to date. This is a pathology presenting atypical clinical manifestations for a bacterial infection and which therefore remains underdiagnosed. Streptobacillus moniliformis infections can be fatal without appropriate antibiotic treatment. This study could improve diagnosis, develop early treatment strategies and contribute to the overall understanding of zoonotic diseases
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 1 Year to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Minor patient aged 1 to 17 years
- •Adult patient ≥18 years
- •Proven Streptobacillus moniliformis infection between 01/01/2007 and 31/12/2023
- •Subject not objecting, after being informed, to the reuse of their data for the purposes of this research
- •Holders of parental authority not objecting, after being informed, to the reuse of their data for the purposes of this research their child for the purposes of this research
Exclusion Criteria
- •Subject and/or holder of parental authority having expressed opposition to participating in the study
Outcomes
Primary Outcomes
Retrospective study of the effectiveness of antibiotic therapy initiated for the treatment of Streptobacillus moniliformis infection.
Time Frame: Negative blood culture 15 days after the start of antibiotic therapy.
Clinical cure 15 days after the start of antibiotic therapy. This cure is based on a negative blood culture (absence of germs) performed 15 days after the start of treatment.
Secondary Outcomes
No secondary outcomes reported